Syngenta and Novozymes are entering the commercialization phase of the biofungicide Taegro. The two companies originally joined forces in 2012 to develop and market the product, and have now received the first wave of product approvals in Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Honduras, Italy, Netherlands, Romania, Slovenia, Spain, and United Kingdom. Several other approvals are expected across the EU and Latin America during the next 12 months, which will enable multiple product launches in 2020.
“We’re delighted to see our collaboration with Novozymes entering the commercialization phase and excited about our launch plans. Over the last seven years, our journey together deepened our understanding of biologicals, and we are pleased to place a new tool in the hands of farmers,” commented Jean-Philippe Albert, Global Head of Disease Control at Syngenta.
“This collaboration matches Syngenta’s global market strength in biocontrol and dedication to bring novel technologies to market with Novozymes’ deep knowledge of sustainable, biological solutions,” said Thomas Batchelor, Novozymes’ Vice President of BioAg Commercial. “As the developer and producer of Taegro, we are really excited to see another microbial technology become available to farmers to help them sustainably combat crop diseases and avoid significant yield losses.”
Taegro is a microbial foliar fungicide with broad spectrum potential. When fruit and vegetable growers use Taegro in the recommended crop management programs it protects against diseases such as powdery mildew and botrytis. Due to its microbial origin, low application rates, and short re-entry and pre-harvest intervals, Taegro is a powerful tool that helps ensure compliance with food chain requirements and maximize marketable yields. The efforts behind the development and commercialization of Taegro demonstrate both companies’ commitment to sustainability.